Benitec Biopharma
BNTC
6 hedge funds and large institutions have $395K invested in Benitec Biopharma in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
17% more capital invested
Capital invested by funds: $337K → $395K (+$58K)
0.1% more ownership
Funds ownership: 0.23% → 0.33% (+0.1%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$110K |
| 2 |
Morgan Stanley
New York
|
+$39K |
| 3 |
Rockefeller Capital Management
New York
|
+$2.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$7.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $219K | +$39K | +323 | +19% |
|
|
CS
2
Credit Suisse
Zurich,
Switzerland
| $98K | +$110K | +916 | New |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $75K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | -$7.12K | -59 | -77% |
|
|
5
Rockefeller Capital Management
New York
| $1K | +$2.17K | +18 | New |
|
|
RE
6
RBC Europe
London,
United Kingdom
| $38 | – | – | – |
|
BNTC Hedge Fund Activity: Q3 2020 in Review
6 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2020, worth a combined $395K — up 17% from $337K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BNTC positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $110K. The largest seller was UBS Group, cutting an estimated $7.12K.
- 6 institutional investors held Benitec Biopharma (BNTC) as of Q3 2020, up from 4 in Q2 2020.
- Funds reported $395K of Benitec Biopharma stock for Q3 2020, up 17% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q3 2020 and 0 closed out, a net change of +2 holders.
- The largest Benitec Biopharma buyer in Q3 2020 was Credit Suisse, an estimated $110K added.
- The largest Benitec Biopharma seller in Q3 2020 was UBS Group, an estimated $7.12K sold.
Based on aggregated 13F filings for Q3 2020.